scholarly journals 2.Surgical Treatment of Clinoidal Meningioma(Morning Seminar-9 Surgery of Skull Base Meningiomas,The 26^ Annual Meeting of The Japanese Congress of Neurological Surgeons)

2006 ◽  
Vol 15 (4) ◽  
pp. 338
Author(s):  
Tooru Inoue
Keyword(s):  
Surgical Treatment ◽  
Skull Base ◽  
Annual Meeting ◽  
Skull Base Meningiomas

Surgical Treatment of Skull Base Meningiomas: Risk Factors and Strategy of Treatment

Skull Base ◽  
2007 ◽  
Vol 16 (S 1) ◽  
Author(s):  
Yuri Aimi ◽  
Kiyoshi Saito ◽  
Takeshi Okada ◽  
Masahiro Ichikawa ◽  
Tetsuya Nagatani ◽  
...  
Keyword(s):  
Risk Factors ◽  
Surgical Treatment ◽  
Skull Base ◽  
Skull Base Meningiomas

scholarly journals Skull base meningiomas: development of treatment methods

2021 ◽  
Vol 23 (3) ◽  
pp. 93-103
Author(s):  
S. E. Zuev ◽  
A. S. Tokarev
Keyword(s):  
Targeted Therapy ◽  
Surgical Treatment ◽  
Skull Base ◽  
Proton Therapy ◽  
Robotic Systems ◽  
Treatment Methods ◽  
Significant Events ◽  
Skull Base Meningiomas

The review describes the treatment methods for skull base meningiomas and promising modern trends in this area. The most significant events in the development of meningiomas’ surgical treatment are described. The current research and scientific approaches to the skull base meningiomas’ treatment are presented: medical robotic systems, targeted therapy, radiosurgery, and proton therapy.

scholarly journals Clinical results of basal meningiomas laser surgery

2008 ◽  
Vol 7 (5-2) ◽  
pp. 399-402
Author(s):  
V. V. Stupak ◽  
A. V. Kalinovsky ◽  
S. V. Maiorov ◽  
S. G. Struts
Keyword(s):  
Laser Radiation ◽  
Surgical Treatment ◽  
Skull Base ◽  
Laser Surgery ◽  
Clinical Results ◽  
Laser Application ◽  
Yag Laser ◽  
Skull Base Meningioma ◽  
Surgical Methods ◽  
Skull Base Meningiomas

Methods of surgical treatment of patients with skull base meningiomas using high intensity infrared laser radiation (ND-YAG laser) at a wavelength of 1.06 micron were developed. The paper presents results of Nd-YAG laser application in skull base meningioma removal with assessment of its efficacy as compared with conventional surgical methods.

Treatment of unresectable skull base meningiomas with somatostatin analogs

2011 ◽  
Vol 30 (5) ◽  
pp. E11 ◽  
Author(s):  
Chris Schulz ◽  
René Mathieu ◽  
Ulrich Kunz ◽  
Uwe Max Mauer
Keyword(s):  
Surgical Treatment ◽  
Mr Imaging ◽  
Skull Base ◽  
Somatostatin Analogs ◽  
Cranial Nerves ◽  
Insurance Company ◽  
Mr Images ◽  
Study Results ◽  
Skull Base Meningiomas ◽  
Tumor Enlargement

Object The standard surgical treatment for meningiomas is total resection, but the complete removal of skull base meningiomas can be difficult for several reasons. Thus, the management of certain meningiomas of the skull base—for example, those involving basal vessels and cranial nerves—remains a challenge. In recent reports it has been suggested that somatostatin (SST) administration can cause growth inhibition of unresectable and recurrent meningiomas. The application of SST and its analogs is not routinely integrated into standard treatment strategies for meningiomas, and clinical studies proving growth-inhibiting effects do not exist. The authors report on their experience using octreotide in patients with recurrent or unresectable meningiomas of the skull base. Methods Between January 1996 and December 2010, 13 patients harboring a progressive residual meningioma (as indicated by MR imaging criteria) following operative therapy were treated with a monthly injection of the SST analog octreotide (Sandostatin LAR [long-acting repeatable] 30 mg, Novartis). Eight of 13 patients had a meningioma of the skull base and were analyzed in the present study. Postoperative tumor enlargement was documented in all patients on MR images obtained before the initiation of SST therapy. All tumors were benign. No patient received radiation or chemotherapy before treatment with SST. The growth of residual tumor was monitored by MR imaging every 12 months. Results Three of the 8 patients had undergone surgical treatment once; 3, 2 times; and 2, 3 times. The mean time after the last meningioma operation (before starting SST treatment) and tumor enlargement as indicated by MR imaging criteria was 24 months. A total of 643 monthly cycles of Sandostatin LAR were administered. Five of the 8 patients were on SST continuously and stabilized disease was documented on MR images obtained in these patients during treatment (median 115 months, range 48–180 months). Three of the 8 patients interrupted treatment: after 60 months in 1 case because of tumor progression, after 36 months in 1 case because of side effects, and after 36 months in 1 case because the health insurance company denied cost absorption. Conclusions Although no case of tumor regression was detected on MR imaging, the study results indicated that SST analogs can arrest the progression of unresectable or recurrent benign meningiomas of the skull base in some patients. It remains to be determined whether a controlled prospective clinical trial would be useful.

Sign in / Sign up

Export Citation Format

Share Document